Zai Lab stock prepares global cancer data for ESMO

Published on 09/30/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zai Lab stock prepares for first global zoci data at ESMO on October 26, 2026. Q2 revenue was USD 106.31 million, while EPS showed a USD 0.50 loss.

ZJM, CA98959U1084, Illustration mit AI erstellt.

Zai Lab stock is preparing for the first global presentation of data on zocilurtatug pelitecan, or zoci, at ESMO on October 26, 2026. The company said in an investor release dated September 29, 2026, that the Phase 1b/1c trial is testing zoci with atezolizumab, with or without carboplatin, in first-line extensive-stage small cell lung cancer, according to Zai Lab.

ESMO sets the next catalyst

The ESMO poster is titled ZL 1310 plus atezolizumab with or without carboplatin in extensive-stage small cell lung cancer. The presentation is scheduled for October 26, 2026, from 12:00 p.m. to 12:45 p.m. CEST, according to Zai Lab.

A separate investor webcast is scheduled for October 23, 2026, at 8:00 a.m. ET. That timing places the clinical update before the poster session and gives investors an earlier checkpoint on the development plan.

Quarterly revenue reached USD 106.31 million

Zai Lab reported second-quarter 2026 revenue of USD 106.31 million and a loss of USD 0.50 per share, according to MarketBeat. The revenue figure was higher than the USD 99.61 million reported for the first quarter of 2026, while the quarterly loss keeps development spending central to the investment case.

MarketBeat also reported an average analyst target of USD 37.25 and a Moderate Buy consensus on September 23, 2026. Compared with the Nasdaq quote of USD 26.40 at 1:29 p.m. EDT on September 30, 2026, the published target was 41.10 percent higher, a gap that depends on continued pipeline execution rather than current earnings.

Market value and pipeline remain linked

Zai Lab's commercial-stage portfolio spans oncology, immunology, neuroscience and infectious disease. The company's zoci program is aimed at a DLL3 target in small cell lung cancer, giving the October data release a direct connection to the broader oncology pipeline.

Nasdaq market value reaches USD 3.0 billion

Zai Lab had a Nasdaq market capitalization of USD 3.0 billion on September 30, 2026. The primary-exchange quote was USD 26.40 at 1:29 p.m. EDT, compared with a 52-week range of USD 15.96 to USD 34.72.